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Abstract
Background: Pulmonary hypertension (PH) is associated with progressive impairment of right ventricular function, reduced
exercise capacity and a poor prognosis. Little is known about the prevalence, clinical manifestation and impact of atrial
fibrillation (AF) on cardiac function in PH.
Methods: In a four year single-centre retrospective analysis 225 patients with confirmed PH of various origins were enrolled
to investigate the prevalence of AF, and to assess the clinical manifestation, 6-minute walk distance, NT-proBNP levels,
echocardiographic parameters and hemodynamics obtained by right heart catheterization in PH with AF.
Results: AF was prevalent in 31.1%. In patients with PH and AF, parameters of clinical deterioration (NYHA/WHO functional
class, 6-minute walk distance, NT-proBNP levels) and renal function were significantly compromised compared to patients
with PH and sinus rhythm (SR). In the total PH cohort and in PH not related to left heart disease occurrence of AF was
associated with an increase of right atrial pressure (RAP) and right atrial dilatation. While no direct association was found
between pulmonary artery pressure (PAP) and AF in these patients, right ventricular function was reduced in AF, indicating
more advanced disease. In PH due to left heart failure the prevalence of AF was particularly high (57.7% vs. 23.1% in other
forms of PH). In this subgroup, left atrial dilatation, increase of pulmonary capillary wedge pressure, PAP and RAP were more
pronounced in AF than in SR, suggesting that more marked backward failure led to AF in this setting.
Conclusion: PH is associated with increased prevalence of AF. Occurrence of AF in PH indicates clinical deterioration and
more advanced disease.
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Introduction
Pulmonary hypertension (PH) – i.e. an elevated mean
pulmonary artery pressure (PAP), $25 mmHg at rest – defines a
group of diseases characterized by a progressive increase in
pulmonary vascular resistance leading to right ventricular failure
and premature death [1,2,3]. Based on the pathophysiological
mechanisms and etiology, the current clinical classification
distinguishes five groups of PH [4]. Left heart failure (HF) is one
common cause of PH, representing group 2 of the Dana-Point
classification. Left ventricular systolic dysfunction, diastolic
dysfunction or valvular disease may all result in elevated PAP.
In fact, PH is being found in more than 60% of patients with
moderate or severe HF [5]. However, from a pathophysiological
point of view and with regard to therapeutic options, PH due to
left heart disease is clearly differentiated from pulmonary arterial
hypertension (PAH) and has to be appreciated as a separate entity.
At present, targeted PAH therapies are not recommended for this
subgroup.
Atrial fibrillation (AF) is the most common chronic arrhythmia.
Chronic left heart failure and AF often coexist. Both are
responsible for increased mortality, more frequent hospitalizations,
reduced exercise capacity, decreased quality of life and substantial
health care expenditures [6]. In addition to merely having risk
factors in common, AF and heart failure are believed to directly
predispose to each other [7,8]. The risk of developing AF during
long-term follow-up appears to be 5 to 10 times higher in patients
with left heart failure than in healthy persons [9,10,11,12]. Some
studies have shown that the onset of AF in these patients is
associated with clinical and hemodynamic deterioration due to loss
of atrial contractility, tachycardia, and lack of atrioventricular
synchrony, as well as a worse long-term prognosis [13,14].
Although the association between AF and left heart failure is
well documented, the predisposing factors for developing AF in
this setting are not fully understood. Moreover, the prevalence of
AF in PH with or without compromised right ventricular function
has not been defined. Learning more about which types of patients
with PH develop AF may yield important insights into the
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PH-SR
(n=155)
PH-AF
(n=70)
Characteristic n % or Mean ± SEM n % or Mean ± SEM
Age 155 62.961.2 70 71.261.1
Male 58 37.4% 25 35.7%
Female 97 62.6% 45 64.3%
Mean heart rate (bpm) 155 79.561.3 70 74.661.9
WHO group | PH subgroup
Pulmonary arterial hypertension 78 50.3% 32 45.7%
Idiopathic 31 20.0% 24 34.3%*
Heritable 2 1.3% 0 0%
Drug- and toxin-induced 4 2.6% 0 0%
Associated with
Congenital heart disease 6 3.9% 3 4.3%
HIV infection 3 1.9% 0 0%
Connective tissue disease 32 20.6% 3 4.3%*
Portal hypertension 0 0% 2 2.9%
Veno-occlusive disease 0 0% 0 0%
Pulmonary hypertension due to left heart failure 22 14.2% 30 42.9%*
Systolic dysfunction 6 3.9% 10 14.3%*
Diastolic dysfunction 13 8.4% 17 24.3%*
Valvular disease 3 1.9% 3 4.3%
Pulmonary hypertension due to pulmonary disease 21 13.5% 5 7.1%
Chronic obstructive pulmonary disease 7 4.5% 3 4.3%
Interstitial lung disease 14 9.0% 2 2.9%
Chronic thromboembolic pulmonary hypertension 31 20.0% 2 2.9%*
Others 3 1.9% 1 1.4%
Medication
Phosphodiesterase-5-inhibitor 51 32.9% 31 44.3%
Endothelin-1 antagonist 47 30.3% 15 21.4%
Prostacyclin 7 4.5% 3 4.3%
Calcium channel blockers 29 18.7% 17 24.3%
Betablocker 65 41.9% 51 72.9%*
Digitalis 8 5.2% 26 37.1%*
Amiodarone 1 0.6% 7 10.0%*
Sotalol 2 1.3% 1 1.4%
Diuretics 112 72.3% 65 92.9%*
Angiotensin receptor blockers/AT-1 antagonist 82 52.9% 42 60.0%
Cumarine 61 39.4% 55 78.6%*
Acetylsalicylic acid 49 31.6% 11 15.7%*
Clopidogrel 10 6.5% 4 5.7%
Statins 41 26.5% 27 38.6%
Nitrates 11 7.1% 3 4.3%
Concomitant disease
Coronary artery disease 39 25.2% 19 27.1%
Myocardial infarction 9 5.8% 8 11.4%
Coronary artery bypass graft 5 3.2% 7 10.0%
Dilated cardiomyopathy 3 1.9% 7 10.0%*
Valvular disease 14 9.0% 20 28.6%*
Arterial hypertension 75 48.4% 45 64.3%*
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guide clinicians in the monitoring, evaluation, and management of
these patients.
Methods
Study participants
The study was performed according to good clinical practice
and in compliance with the Helsinki declaration. Individual
patient were not identified. An individual written consent was
obtained by every patient, which is usually performed due to
quality management issues in our hospital. The study and study
design was approved by the institutional review board. The study
cohort comprised 225 consecutive patients with confirmed
diagnosis of PH referred to a single-centre between October 01,
2006 and March 31, 2010. In all eligible patients, exact
classification of PH into one of the five groups according to the
Dana-Point classification was performed [4], and information
about the clinical severity (NYHA/WHO functional class),
medication, concomitant diseases, 6-minute walk distance and
N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were
obtained from the University Patient Database. Furthermore, if
available, echocardiography was analyzed. Patients were divided
into two groups: 1. patients with PH and sinus rhythm (PH-SR)
and 2. patients with PH and atrial fibrillation (PH-AF). Given
distinct cardiac pathomechanisms, subgroup analysis was per-
formed in patients with PH due to left heart failure (a. PH-HF SR
and b. PH-HF AF) and PH due to any other cause (c. PH-nonHF
SR and d. PH-nonHF AF).
Definition of prevalent AF
‘‘Prevalent AF’’ was defined as the presence of AF on
electrocardiogram during the index hospitalization and/or as
indicated by a diagnosis found in medical records, the hospital-
ization database, or ambulatory visit databases. ‘‘Electrocardio-
graphic AF’’ was defined as the presence of an irregular rhythm
with fibrillatory waves and no defined P-waves [9]. Diagnoses were
based on physician-assigned diagnoses in the medical records and/
or the presence of corresponding ICD-9-CM codes for AF (427.31)
in the hospital discharge or ambulatory visit clinical databases.
Atrial fibrillation was sub-classified into paroxysmal AF or chronic
AF (persistent or permanent) according to international guidelines.
Etiology and severity of PH
Patients were classified according to the Dana Point classifica-
tion of PH, and clinical severity was assessed according to the
WHO functional classes for PH [4]. In PH due to left heart failure
with reduced ejection fraction, left ventricular ejection fraction was
defined as lower than 40% (as assessed by echocardiography,
biplane Simpson method in apical four chamber view). Heart
failure with preserved ejection fraction was diagnosed following
the consensus statement of the Association of the European
Society of Cardiology [15]. Valvular disease was defined as mitral
and/or aortic stenosis or insufficiency or valve repair.
Six-minute walk testing
Patients were instructed to walk down a 100-foot corridor at
their own pace, attempting to cover as much ground as possible.
At the end of the six minute interval the total distance was
determined. The test was performed by personnel that had been
trained according to the current ATS consensus statement on six-
minute walk testing [16]. Forty-two patients were excluded from
testing due to disability of movement.
Clinical laboratory parameters
N-terminal pro-brain natriuretic peptide (NT-proBNP) was
measured in every patient as a marker of heart failure known to
correlate with survival and the severity of disease in both left and
right heart failure. Additionally, renal function parameters, i.e.
creatinine, urea nitrogen and estimated glomerular filtration rate
(eGFR, using the MDRD equation [17]) were determined.
Echocardiography
All transthoracic echocardiographic studies were obtained by
experienced investigators using a Philips iE 33 echocardiography
system (Philips, Hamburg, Germany). Left atrial diameter (edge-
to-edge method, parasternal view), right atrial area (measured at
end-systole in the apical four chamber view), left ventricular
ejection fraction (biplane Simpson method), Tricuspid Annular
Plane Systolic Excursion (TAPSE) and pulmonary artery systolic
pressure were recorded according to current recommendations
[18]. Only complete datasets were included in the statistical
analysis.
Right heart catheterization
Right heart catheterization was performed via the femoral vein
using a balloon flotation catheter (PWP catheter, Medtronic,
Minneapolis, USA). Fluoroscopic guidance was used to cannulate
the pulmonary artery and obtain pulmonary capillary wedge
position. Right heart catheterization studies were analyzed for
systolic and mean pulmonary arterial pressure, pulmonary
capillary wedge pressure (PCWP), right atrial pressure and
pulmonary vascular resistance. Cardiac output was estimated
using the Fick technique. Echocardiograms and right heart
catheterization were performed at the same time.
Statistical analysis
Statistical analyses were performed using PASW statistics 18
software (SPSS, Chicago, USA). All variables were tested for
normal distribution with the Kolmogorov-Smirnov test. The
results are given as mean 6 standard error of mean (SEM). All
groups and subgroups were compared for PH classification,
clinical manifestation, 6-minute-walk-testing, laboratory parame-
ters, data of echocardiography and right heart catheterization.
Table 1. Cont.
PH-SR
(n=155)
PH-AF
(n=70)
Characteristic n % or Mean ± SEM n % or Mean ± SEM
Pulmonary disease 97 62.6% 27 38.6%*
*p,0.05 vs. PH-SR.
doi:10.1371/journal.pone.0033902.t001
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square-testing for discrete variables and student-t test for
continuous variables. For ordinal data Mann-Whitney-U test
was used. A p,0.05 was considered as statistically significant.
Results
Baseline characteristics and prevalence of AF
Atotalof225patientswithPHwereanalyzedinthisretrospective
study. Seventy patients (31.1%) of the total study cohort had
evidence of AF. In patients with AF, 41.3% had paroxysmal AF,
whereas 58.7% presented with chronic AF. The demographic
variables of the individual groups with and without AF are shown
in table 1. Patients in both groups were predominantly female.
Mean age did not differ significantly between the PH-SR and PH-
AF group.
When evaluating the relative percentage of the distinct
etiologies of PH according to the Dana Point classification in the
PH-AF group versus PH-SR group, we obtained no significant
difference for PH due to pulmonary disease. However, PH due to
left heart failure (PH-HF) was markedly more common in the PH-
AF group (PH-AF 42.9% vs. PH-SR 14.2%, p,0.05). This
observation was consistent for all causes of left heart failure,
though for valvular disease the difference did not reach statistical
significance most likely due to the limited number of patients in
this subgroup (table 1). Notably, 57.7% of all patients with PH-HF
presented with AF, compared to 23.1% in the PH-nonHF group.
Conversely, the relative percentage of chronic thromboembolic
pulmonary hypertension (CTEPH) was higher in the PH
population with SR (PH-SR 20.0% vs. PH-AF 2.9%, p,0.05).
While we observed a similar percentage of pulmonary arterial
hypertension (PAH) per se in the PH-AF and PH-SR group
(45.7% vs. 50.3%, n.s.), idiopathic PAH was more frequent in
those with AF (PH-AF 34.3% vs. PH-SR 20.0%, p,0.05),
reflecting an AF prevalence of 43.6% in this subpopulation.
A comparison of patients with paroxysmal (PH-AF paroxysmal)
and chronic (PH-AF chronic) AF in PH revealed chronic AF to be
associate with PH due to pulmonary disease (PH-AF paroxysmal
0% vs. PH-AF chronic 11.9%, p,0.05). Moreover, PH due to
systolic dysfunction was associated with chronic AF, while diastolic
dysfunction was related to paroxysmal AF (systolic dysfunction:
Figure 1. Laboratory parameters and exercise capacity in PH with and without AF. NT-pro-BNP, estimated glomerular filtration rate (eGFR),
urea nitrogen (BUN) and 6-minute walk distance of patients with PH were compared in those with AF (PH-AF) and SR (PH-SR). * p,0.05. Error bars
representing standard error of mean.
doi:10.1371/journal.pone.0033902.g001
Table 2. Effect of AF on NYHA class and renal function in PH.
PH-SR PH-AF
NYHA classification n % n %
NYHA I 2 1.3% 0 0%
#
NYHA II 52 33.5% 17 24.3%
#
NYHA III 98 63.2% 51 72.9%
#
NYHA IV 3 1.9% 2 2.9%
#
Renal function
CKD class I 31 20.0% 3 4.3%
#
CKD class II 62 40.0% 23 32.9%
#
CKD class III 55 35.5% 35 50.0%
#
CKD class IV 6 3.9% 8 11.4%
#
CKD class V 1 0.6% 1 1.4%
#
CKD=Chronic kidney disease classification.
#p,0.05 vs. PH-SR.
doi:10.1371/journal.pone.0033902.t002
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diastolic dysfunction: PH-AF paroxysmal 32.1% vs. PH-AF
chronic 19.0%, p,0.05).
Targeted therapy for PAH such as prostacyclin analogues,
endothelin receptor antagonists and phosphodiesterase-5 inhibi-
tors were equally prescribed in PAH patients with and without AF.
Expectedly, treatment for AF, i.e. betablockers, digitalis, amioda-
rone and cumarine was more common in the PH-AF group.
Notably, patients with PH-AF more often received diuretics
indicating more advanced heart failure.
Clinical presentation of patients with AF in PH
Thus far, clinical manifestation of AF in PH has not been
analyzed systematically. Therefore, we evaluated functional class,
exercise capacity, and laboratory parameters indicative of
hemodynamic status in this population. The clinical condition in
patients with AF in PH was more severe than in patients without
AF, as indicated by the NYHA/WHO functional class (table 2).
Consistently, the 6-minute walk distance was significantly shorter
in the PH-AF group (PH-SR vs. PH-AF: 355.5569.86 m, n=130
vs. 321.98614.1 m, n=53; p,0.05, figure 1). Moreover, in
patients with AF, the elevation of NT-proBNP serum levels was
more pronounced (PH-SR vs. PH-AF: 2128.886429.97 ng/l,
n=155 vs. 3252.796401.76 ng/l, n=70; p,0.05, figure 1).
Given that renal failure was shown to correlate with reduced
survival and clinical deterioration, standard parameters of renal
function (creatinine, urea nitrogen, eGFR) and chronic renal
failure classification were analyzed. As shown in figure 1, AF was
associated with impaired renal function, reflected by a significant
Figure 2. Hemodynamic parameters associated with AF in PH. Left atrial (LA) diameter and right atrial (RA) area were measured by
echocardiography in PH-AF compared to PH-SR. PCWP and mean right atrial pressure (RAPmean) were obtained by right heart catheterization in the
presence (PH-AF) or absence (PH-SR) of AF in patients with PH. * p,0.05.
doi:10.1371/journal.pone.0033902.g002
Table 3. Effect of AF on hemodynamic parameters in PH.
PH-SR PH-AF
Echocardiography n
Mean ±
SEM n
Mean ±
SEM
Left atrial diameter [mm] 154 37.0960.64 69 46.1661.28*
Right atrial area [mm
2] 154 23.1560.62 69 28.5961.19*
TAPSE [mm] 154 20.9760.48 69 18.0760.68*
Systolic pulmonary artery pressure
[mmHg]
154 64.5961.82 69 60.1062.18
Left ventricular ejection fraction [%] 154 63.8160.55 69 59.8461.52*
Right heart catheterization
Systolic pulmonary artery pressure
[mmHg]
155 65.0061.86 70 67.5162.34
Mean pulmonary artery pressure
[mmHg]
155 40.2561.12 70 40.8061.56
Mean right atrial pressure [mmHg] 135 9.460.43 61 12.8560.86*
PCWP [mmHg] 155 11.9660.38 70 16.5060.90*
Pulmonary vascular resistance [Wood
units]
146 7.2960.42 66 6.4560.54
Cardiac output [l/min] 127 4.3660.12 47 3.9160.16*
*p,0.05 vs. PH-SR.
doi:10.1371/journal.pone.0033902.t003
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AF compared to those without AF (PH-SR vs. PH-AF:
1.0760.03 mg/dl, n=154 vs. 1.3760.11 mg/dl, n=73;
49.1761.97 mg/dl, n=154 vs. 72.6165.44 mg/dl, n=69;
p,0.05), and a reduced eGFR (PH-SR vs. PH-AF:
69.6862.11 ml/min, n=154 vs. 54.9662.65 ml/min, n=69;
p,0.05). Accordingly, patients with AF in PH were found to be
in more severe stages of chronic renal failure (table 2).
Hemodynamic parameters in PH with AF
Cardiac function and hemodynamic data were evaluated by
echocardiography and right heart catheterization (table 3). Expect-
edly, left atrial diameter was significantly larger, pulmonary
capillary wedge pressure (PCWP) was higher (figure 2, table 3),
and left ventricular ejection fraction was reduced in the PH-AF
group, reflecting the marked fraction of PH due to left heart disease.
Notably, systolic and mean pulmonary artery pressures showed
no differences in the PH-AF compared to the PH-SR group,
implicating that pulmonary artery pressure per se has no direct
effect on the occurrence of AF or vice versa. However, we obtained
a significant increase of the right atrial area and mean right atrial
pressure in PH with versus without AF (figure 2, table 3). Moreover,
right ventricular function assessed by TAPSE was significantly
reduced in PH-AF. Consistently, cardiac output was lower in the
PH-AF group compared to the PH-SR group (table 3).
A comparison of patients with paroxysmal (PH-AF paroxysmal)
and chronic (PH-AF chronic) AF in PH indicated increased right
atrial area and mean right atrial pressure in patients with chronic
AF versus paroxysmal AF (PH-AF paroxysmal 25.0461.46 mm
2
and 10.6960.98 mmHg vs. PH-AF chronic 30.9361.36 mm
2 and
14.9161.03 mmHg, p,0.05).
AF in PH not related to left heart disease
Given the distinct pathopyhsiology of pre- versus postcapillary
PH, in a subanalysis patients with PH due to left heart disease (PH-
HF, group 2) were separated from patients with PH due to any
Table 4. Comparison of subgroups with SR vs. AF in PH not related to left heart disease (nonHF).
PH-SR nonHF PH-AF nonHF
Echocardiography n % or Mean ± SEM n % or Mean ± SEM
Left atrial diameter [mm] 132 37.0560.68 39 43.3161.55*
Right atrial area [mm
2] 132 23.5360.66 38 30.5161.61*
TAPSE [mm] 132 20.7460.52 38 18.3560.87*
Systolic pulmonary artery pressure [mmHg] 132 66.6761.98 39 65.7263.15
Left ventricular ejection fraction [%] 132 64.5260.43 40 64.3061.16
Right heart catheterization
Systolic pulmonary artery pressure [mmHg] 133 67.0262.04 40 68.2563.24
Mean pulmonary artery pressure [mmHg] 133 41.2561.23 40 40.3862.04
Mean right atrial pressure [mmHg] 115 8.9360.45 36 11.0360.63*
PCWP [mmHg] 133 10.8660.30 40 12.3560.63
Pulmonary vascular resistance [Wood units] 126 7.7460.46 38 7.1660.75
Cardiac output [l/min] 111 4.3660.13 25 3.9460.19
Laboratory parameters
NT-proBNP [pg/l] 133 1738.866212.05 40 3449.406547.61*
Creatinine [mg/dl] 133 1.0660.03 40 1.2360.08*
Urea nitrogen [mg/dl] 133 48.2362.10 40 64.4065.39*
eGFR [ml/min//1.72 m
2] 133 70.7862.34 40 58.1863.51*
NYHA classification
NYHA I 1 0.8% 0 0%
#
NYHA II 51 38.3% 8 20.0%
#
NYHA III 78 58.6% 31 77.5%
#
NYHA IV 3 2.3% 1 2.5%
#
6-minute walk test
6-minute walk test [m] 113 364.67610.51 31 303.87617.36*
Renal function
CKD class I 28 21.1% 2 5.0%
#
CKD class II 56 42.1% 15 37.5%
#
CKD class III 43 32.3% 20 50.0%
#
CKD class IV 6 4.5% 3 7.5%
#
CKD class V 0 0% 0 0%
#
CKD=Chronic kidney disease classification, eGFR=estimated glomerular filtration rate.
*p,0.05 vs. PH-SR (student t-test).
#p,0.05 vs. PH-SR (Mann-Whitney test).
doi:10.1371/journal.pone.0033902.t004
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left heart disease, AF was observed in 23.1% (table 4). In PAH
(group 1) AF was found in 29.1% (table 5). AF was associated with
clinical deterioration, as indicated by a higher NYHA/WHO
functional class, shorter 6-minute walk distance, more severely
elevated NT-proBNP serum levels and compromised renal
function compared to patients in SR (table 4, table 5).
While consistent with the total PH cohort, no difference of
systolic and mean pulmonary arterial pressures in the presence or
absence of AF was obtained; increased right atrial pressure and
size as well as reduced right ventricular function were the most
obvious hemodynamic differences between prevalent AF versus no
AF in PH-nonHF and PAH. As expected, left ventricular ejection
fraction and PCWP were similar in both groups (table 4, table 5).
AF in left heart disease with PH
In patients with PH due to left heart disease, AF was prevalent
in 57.7%. While AF in this cohort did not further diminish
exercise capacity or NYHA/WHO functional class, we still
observed higher NT-proBNP values and more severely compro-
mised renal function in those patients with AF versus SR (table 6).
Left atrial size was significantly larger and PCWP tended to be
higher in prevalent AF, although the latter did not reach statistical
significance. Invasive measurements demonstrated increased
systolic and mean pulmonary arterial and right atrial pressures
associated with AF. Moreover, echocardiography indicated right
heart impairment, i.e. increased right atrial area and suppressed
TAPSE in the subgroup with prevalent AF (table 6).
Discussion
Atrial fibrillation affects 1–2% of the general population. The
prevalence of AF increases with age, from 0.5% at 40–50 years, to
5–15% at 80 years [19]. Atrial fibrillation is highly prevalent
among patients with left ventricular heart failure, and can lead to
adverse consequences, including tachycardia-related cardiomyop-
Table 5. Comparison of subgroups with SR vs. AF in PAH.
PAH-SR PAH-AF
Echocardiography n % or Mean ± SEM n % or Mean ± SEM
Left atrial diameter [mm] 77 37.0460.81 31 43.6161.53*
Right atrial area [mm
2] 77 22.9260.87 31 31.3361.49*
TAPSE [mm] 77 20.9960.65 31 17.7460.94*
Systolic pulmonary artery pressure [mmHg] 77 62.8362.62 31 66.5863.38
Left ventricular ejection fraction [%] 77 64.4960.49 32 64.0661.40
Right heart catheterization
Systolic pulmonary artery pressure [mmHg] 78 65.2762.31 32 70.0363.83
Mean pulmonary artery pressure [mmHg] 78 41.2261.73 32 41.4762.45
Mean right atrial pressure [mmHg] 66 8.9060.49 32 11.4360.65*
PCWP [mmHg] 78 10.5360.38 32 12.8460.63
Pulmonary vascular resistance [Wood units] 74 7.4960.60 32 7.5860.87
Cardiac output [l/min] 66 4.4160.19 21 3.9860.26
Laboratory parameters
NT-proBNP [pg/l] 78 1705.816232.49 32 3529.846537.77*
Creatinine [mg/dl] 78 1.0660.04 32 1.3860.09*
Urea nitrogen [mg/dl] 78 45.9862.38 32 68.1964.55*
eGFR [ml/min//1.72 m
2] 78 73.7663.47 32 59.0963.09*
NYHA classification
NYHA I 1 1.3% 0 0%
#
NYHA II 35 44.9% 7 21.9%
#
NYHA III 41 52.6% 24 75.0%
#
NYHA IV 1 1.3% 1 3.1%
#
6-minute walk test
6-minute walk test [m] 66 384.21611.67 26 311.35618.04*
Renal function
CKD class I 20 25.6% 2 6.3%
#
CKD class II 30 38.5% 13 40.6%
#
CKD class III 24 30.8% 15 46.9%
#
CKD class IV 4 5.1% 2 6.3%
#
CKD class V 0 0% 0 0%
#
CKD=Chronic kidney disease classification, eGFR=estimated glomerular filtration rate.
*p,0.05 vs. PAH-SR (student t-test).
#p,0.05 vs. PAH-SR (Mann-Whitney test).
doi:10.1371/journal.pone.0033902.t005
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disorganized atrial contractions, increased risk of systemic
embolism, and overall poorer long-term outcome [20,21,22].
Supraventricular tachyarrhythmias occurred in patients with
pulmonary hypertension with an annual incidence of 2.8%. Atrial
flutter and atrial fibrillation were equally common and both
arrhythmias led to acute clinical deterioration with signs of right
heart failure, while only atrial fibrillation exerted an impact on
mortality [23]. However, little is known about the total prevalence
of AF in patients with PH and possible differences among distinct
etiological groups of PH have not been defined. In the present
cohort of patients with confirmed PH of various origins, we found
that AF affected approximately one-third of patients. Thus, the
prevalence of AF in PH is considerably higher than in the normal
population at similar age [24]. This was also true for all PH
subgroups except for patients with chronic thromboembolic
pulmonary hypertension (CTEPH).
Particularly, more than half of the patients with PH related to
left heart disease were affected by AF. Symptomatic heart failure
has been reported in 30% of AF patients and AF is found in up to
30% of heart failure patients, depending on the underlying cause
and severity of heart failure [9,19]. Pulmonary hypertension in
heart failure is associated with a poor prognosis and an increased
severity of disease [5]. Compared to the cited populations
mentioned above we observed a significantly higher prevalence
of AF in patients with left heart disease combined with PH
(57.7%), supporting the notion that our patients suffered from
more severe heart failure, which was also indicated by the high
prevalence of patients with NYHA III and markedly elevated NT-
proBNP levels. Moreover, these data suggest that more advanced
heart failure leading to PH is a relevant risk factor for the
development of AF. Given the retrospective design of our study,
we may even have underestimated the true prevalence of AF in
PH. Diagnosis of AF was made by carefully analyzing patient’s
Table 6. Comparison of subgroups with SR vs. AF in PH related to left heart disease (HF).
PH-SR HF PH-AF HF
Echocardiography n % or Mean ± SEM n % or Mean ± SEM
Left atrial diameter [mm] 22 37.3661.89 30 49.8761.96*
Right atrial area [mm
2] 22 20.8761.65 30 26.1761.69*
TAPSE [mm] 22 22.3261.25 29 17.4560.94*
Systolic pulmonary artery pressure [mmHg] 22 52.1463.75 30 52.8062.34
Left ventricular ejection fraction [%] 22 59.5562.69 29 53.6962.90
Right heart catheterization
Systolic pulmonary artery pressure [mmHg] 22 52.8663.29 30 64.1063.36*
Mean pulmonary artery pressure [mmHg] 22 34.2362.01 30 41.3762.46*
Mean right atrial pressure [mmHg] 20 12.1061.16 25 16.9261.37*
PCWP [mmHg] 22 18.6361.21 30 22.1361.37
Pulmonary vascular resistance [Wood units] 20 4.4860.77 28 5.5060.77
Cardiac output [l/min] 16 4.3360.26 22 3.8960.28
Laboratory parameters
NT-proBNP [pg/l] 22 1149.006181.61 30 3257.306568.65*
Creatinine [mg/dl] 21 1.1160.06 29 1.5860.25*
Urea nitrogen [mg/dl] 21 55.1065.60 29 83.93610.35*
eGFR [ml/min//1.72 m
2] 21 62.7164.27 29 50.5263.97*
NYHA classification
NYHA I 2 9.1% 0 0.0%
NYHA II 4 18.2% 11 36.7%
NYHA III 16 72.7% 19 63.3%
NYHA IV 0 0% 0 0%
6-minute walk test
6-minute walk test [m] 17 294.88624.29 22 333.41623.99
Renal function
CKD class I 3 13.6% 1 3.3%
#
CKD class II 8 36.4% 8 26.7%
#
CKD class III 10 45.5% 15 50.0%
#
CKD class IV 0 0% 5 16.7%
#
CKD class V 1 4.5% 1 3.3%
#
CKD=Chronic kidney disease classification, eGFR=estimated glomerular filtration rate.
*p,0.05 vs. PH-SR (student t-test).
#p,0.05 vs. PH-SR (Mann-Whitney test).
doi:10.1371/journal.pone.0033902.t006
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of other means of rhythm monitoring (i.e. periodical Holter
recordings, implanted event recorders), it is likely that some self-
limiting silent AF episodes might have been missed.
When analyzing hemodynamic factors promoting AF in PH it
seems plausible to separately evaluate patients with and without
left heart disease. Previously, reduced left ventricular function,
elevated end-diastolic left ventricular pressure and, thus, higher
PCWP and larger left atrial diameter have been associated with an
increased propensity of AF in left heart disease. Consistently, in the
present study these parameters were more severely altered in
prevalent AF than in patients with SR. Notably, in PH-HF with
AF we observed increased pulmonary artery pressures in invasive
measurements, which are more accurate than echocardiographic
estimation [25], and signs of right heart impairment, indicating
that AF in PH related to left heart disease was associated with
more marked backward failure compared to SR.
Thus far, hemodynamic factors that might contribute to onset of
AF in PH not related to left heart disease have not been evaluated. In
the present analysis, elevated right atrial pressure and right atrial
dilatation were the most prominent parameters associated with
prevalent AF in PH-nonHF. While systolic and mean pulmonary
pressures did not directly correlate with AF occurrence in nonHF
patients, the severity of pulmonary hypertension might have been
masked by impairment of right ventricular function, thus rather
supporting the notion that AF is more common in more advanced
PH. These results provide insight into the possible pathophysiology of
AF in PH and indicate a different pathomechanism of AF induction
in PH with versus without left heart disease. In the absence of left
heart disease (i) left atrial pressure does not play a pathophysiological
role and (ii) pulmonary artery pressure does not seem to provoke AF
by itself, but an increase in right atrial pressure leading to right atrial
dilatation seems to be responsible for onset of AF.
There is only limited data available regarding the clinical
consequences of AF in patients with various forms of PH. Previous
studies indicated that elevated heart rate might lead to increased
mortality in patients suffering from PH. Notably, mean heart
frequency in PH-AF was not significantly different compared to
PH-SR in our population.
The influence of AF on clinical performance and cardiac
function in PH has not been investigated yet. In our cohort
patients with PH-AF demonstrated significant impairment in
NYHA/WHO functional class and 6-minute walk distance
compared to PH-SR. This clinical deterioration in the presence
of AF was also evident by the higher prescription rate of diuretics.
Elevation of NT-proBNP as a marker for heart failure and renal
insufficiency have been implicated to correlate with prognosis and
severity of disease in PH. In the present study these laboratory
parameters were consistently increased in the total PH population
and in all subgroups with prevalent AF compared to SR, further
supporting the notion that AF in PH is associated with more
advanced compromise of hemodynamic function.
Recently, renal failure, reduced 6-minute walk distance,
elevated mean right atrial pressure, and increased brain natriuretic
peptide have been suggested as independent predictors of
mortality in PH. Therefore, it remains to be determined in a
larger prospective study whether AF in PH is just a marker of
more advanced disease, is an independent risk factor, and/or if
cardioversion might improve symptoms, exercise capacity and
possibly prognosis in this population.
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